

MyCartis Evaluation: An integrated multiplex biomarker platform for research and clinical application

At MyCartis, people strongly believe in bringing personalized diagnostics to healthcare. To achieve this goal, disruptive technologies allowing the measurement of syndromic biomarker panels are needed.

MyCartis offers a new microfluidic biomarker analysis platform called Evaluation to serve the research and clinical market. On the surface of digitally encoded microparticles, assays of different types (immune, molecular, other) are developed. When mixed and layered in a microfluidic channel of a 16-channel cartridge, these microparticles form the basis of a multiplex assay with demonstrated superior technical and analytical specifications.

The Evaluation technology now provides researchers the opportunity to easily build custom multiplex assays to study their biomarkers, and diagnostic companies to commercialize them on a platform that integrates pre-analytical and detection workflows, all without the need to ever change platform.

MyCartis is developing a portfolio of assays and offers opportunities for partners to develop their assays on the Evaluation platform.

contact

Wouter Laroy, VP Scientific Marketing

MyCartis

Technologiepark 4, 9052 Ghent-Zwijnaarde, Belgium

Tel: +32 9 241 11 40

Email: wlaroy@mycartis.net